IMMUCELL CORP (ICCC) Stock Overview
NASDAQ:ICCC - US4525253062 - Common Stock
ICCC Key Statistics, Chart & Performance
The current stock price of ICCC is 6.4 USD. In the past month the price increased by 6.67%. In the past year, price increased by 71.12%.
ICCC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.87 | 371.68B | ||
| AMGN | AMGEN INC | 13.19 | 154.89B | ||
| GILD | GILEAD SCIENCES INC | 14.6 | 140.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.08 | 100.25B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.72 | 61.55B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 58.53B | ||
| ARGX | ARGENX SE - ADR | 76.83 | 43.59B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.16 | 36.38B | ||
| INSM | INSMED INC | N/A | 28.77B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.04B | ||
| NTRA | NATERA INC | N/A | 23.09B | ||
| BIIB | BIOGEN INC | 8.26 | 19.38B |
Related stock screener links
About ICCC
Company Profile
ImmuCell Corp. engages in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company is headquartered in Portland, Maine and currently employs 69 full-time employees. The firm is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. The company operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Company Info
IMMUCELL CORP
56 Evergreen Drive
Portland MAINE 04103 US
CEO: Michael F. Brigham
Employees: 72
Phone: 12078782770
IMMUCELL CORP / ICCC FAQ
What is the stock price of IMMUCELL CORP today?
The current stock price of ICCC is 6.4 USD. The price increased by 4.58% in the last trading session.
What is the ticker symbol for IMMUCELL CORP stock?
The exchange symbol of IMMUCELL CORP is ICCC and it is listed on the Nasdaq exchange.
On which exchange is ICCC stock listed?
ICCC stock is listed on the Nasdaq exchange.
What is IMMUCELL CORP worth?
IMMUCELL CORP (ICCC) has a market capitalization of 57.92M USD. This makes ICCC a Micro Cap stock.
How many employees does IMMUCELL CORP have?
IMMUCELL CORP (ICCC) currently has 72 employees.
What are the support and resistance levels for IMMUCELL CORP (ICCC) stock?
IMMUCELL CORP (ICCC) has a support level at 6.11 and a resistance level at 6.47. Check the full technical report for a detailed analysis of ICCC support and resistance levels.
Should I buy IMMUCELL CORP (ICCC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ICCC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ICCC, evaluating the profitability, health, valuation and growth aspects
- IMMUCELL CORP (ICCC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- IMMUCELL CORP (ICCC) Sales and EPS estimates to see what analysts future expectations are.
- IMMUCELL CORP (ICCC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- IMMUCELL CORP (ICCC) Insider and Institutional Ownership to learn about the owners and their transactions.
- IMMUCELL CORP (ICCC) Stock Chart to make your own analysis
- IMMUCELL CORP (ICCC) Latest news and press-releases to stay up to date.
Does IMMUCELL CORP (ICCC) stock pay dividends?
ICCC does not pay a dividend.
When does IMMUCELL CORP (ICCC) report earnings?
IMMUCELL CORP (ICCC) will report earnings on 2025-11-11.
What is the Price/Earnings (PE) ratio of IMMUCELL CORP (ICCC)?
The PE ratio for IMMUCELL CORP (ICCC) is 33.68. This is based on the reported non-GAAP earnings per share of 0.19 and the current share price of 6.4 USD. Check the full fundamental report for a full analysis of the valuation metrics for ICCC.
What is the Short Interest ratio of IMMUCELL CORP (ICCC) stock?
The outstanding short interest for IMMUCELL CORP (ICCC) is 0.19% of its float. Check the ownership tab for more information on the ICCC short interest.
ICCC Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to ICCC. When comparing the yearly performance of all stocks, ICCC is one of the better performing stocks in the market, outperforming 88.13% of all stocks.
ICCC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ICCC. ICCC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ICCC Financial Highlights
Over the last trailing twelve months ICCC reported a non-GAAP Earnings per Share(EPS) of 0.19. The EPS increased by 135.85% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.6% | ||
| ROE | -0.94% | ||
| Debt/Equity | 0.3 |